Carboxyalkyl heterocyclic derivatives

Details Carboxyalkyl heterocyclic derivatives Carboxyalkyl heterocyclic derivatives

1995-12-19

1999-06-15

Dees, Jose' G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514386, 514389, 514392, 514275, 514396, 514402, 514269, 544300, 544302, 544309, 544311, 544314, 544319, 5483175, 5483195, 5483191, C07D23366, C07D23902, C07D23374, A61K 31415

Patent

active

059122617

ABSTRACT:
Carboxyalkyl heterocyclic derivatives, pharmaceutically acceptable salts thereof, and therapeutic agents containing said compounds as an effective component are useful pharmaceuticals for the treatment of diabetic complications such as diabetic neuropathy, diabetic cataracts and retinopathy, diabetic nephropathy, diabetic dermopathy, and other diabetic microangiopathy. The compounds of the present invention are represented by the following general formula (A): ##STR1## The compounds of the present invention exhibit excellent inhibitory action towards aldose reductase with a high enzyme selectivity. Accordingly, they are useful as drugs for the therapy and prevention of various types of diabetic complications without substantially inhibiting aldehyde reductase.

REFERENCES:
patent: Re32919 (1989-05-01), Sarnoff
patent: 3818031 (1974-06-01), Baerlocher et al.
patent: 4096130 (1978-06-01), Kraft et al.
patent: 4647574 (1987-03-01), Ienaga et al.
patent: 4656034 (1987-04-01), Sarnoff
patent: 4661469 (1987-04-01), Sarnoff
patent: 4683240 (1987-07-01), Ienaga et al.
patent: 4772585 (1988-09-01), Sarnoff et al.
patent: 4985453 (1991-01-01), Ishii et al.
patent: 5002930 (1991-03-01), Sarnoff et al.
patent: 5084473 (1992-01-01), Mikami et al.
Grangier et al., (CAS online print out of CA 122:187438, abstract of J. Hetrocyclic Chem. (1994), 31 (6), 1707-14.
Malamas et al., CAS online print out of CA 114:247224, abstract of J. Med. Chem. (1991), 34(4), 1492-503.
Brownlee, et al., "Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking", Science, vol. 232, 1986, pp. 1629-1632.
Ishii, et al., "Highly Selective Aldose Reductase Inhibitors", J. Med Chem., vol. 39, No. 9, 1996, pp. 1924-1927.
Kotani, et al., "Highly Selective Aldose Reductase Inhibitors. 3." J. Med Chem., vol. 40, No. 5, 1997, pp. 684-694.
Kotani, et al., Highly Selective Aldose Redfuctase Inhibitors. II, Chem. Pharm. Bull., vol. 45, No. 2, 1997, pp. 297-304.
Malamas et al. (J. Med. Chem. (1991), vol. 34, pp. 1492-1503).
Grangier et al. (J. Heterocyclic Chem., 31, 1707, 1994).
CA 60:532c, (Mitsubishi Chemical Industries Co. Ltd., (by Masatsune Sato). ('63), Japan, 15, 392).
K. Ogawva, et al., "Syntheses of substituted 2,4-dioxo-thienopyrimidin-1-acetic acids and their evaluation as aldose reductase inhibitors", European Journal of Medicinal Chemistrychimica Therapeutica, vol. 28, No. 10, 1993, pp. 769-781.
Kanazu, et al., "Aldehyde reductase is a major protein associated with 3-deoxyglucosone reductase activity in rat, pig and human livers", Biochem J., 279, 903-906 (1991).
Flynn, "Aldehyde Reductases: Monomeric Nadph-Dependent Oxidoreductases With Multifunctional Potential", Biochem. Pharmacol., vol. 31, No. 17, 2705-2712 (1982).
Patton, J. Org. Chem., 32, No. 2, pp. 383-388 (1967).
Krasnov et al., (CA 119:8771, abstract of Zh. Org. Khim. (1992), 28(7), 1531-7.
Ishii et al. (CA 119:180804, abstract of JP 05043555) 1993.
Henmi et al. (CA 113:23919 abstract of JP 02019363) 1990.

Affiliated with

Also associated with

Rating

Carboxyalkyl heterocyclic derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carboxyalkyl heterocyclic derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxyalkyl heterocyclic derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-402812